Most Popular - Investors received word Monday morning of a positive ruling on Jazz Pharmaceuticals’ (NASDAQ:JAZZ) Xyrem patent case with Roxane Laboratories, a subsidiary of Boehringer Ingelheim. In 2010, … Continue Reading
Read NowMost Popular - Complete Genomics (NASDAQ:GNOM) announced that it has reached buy-out terms with Chinese pharmaceutical company BGI-Shenzhen, in which GNOM will be sold for $117.6M, or $3.15/share. … Continue Reading
Read NowLong Ideas - Reports from Bloomberg that Amarin Corp. (NASDAQ:AMRN) has pulled out of the UBS Global Life Sciences Conference next week is leading some analysts to the … Continue Reading
Read NowLong Ideas - Amarin (NASDAQ:AMRN) announced on Monday that it is unlikely Vascepa’s regulatory exclusivity will be listed in the August Orange Book supplement, due out in mid-September. … Continue Reading
Read NowMost Popular - Cell Therapeutics (NASDAQ:CTIC) closed 10% higher on Monday in anticipation of positive trial data from management at the Rodman & Renshaw Conference in NYC. The … Continue Reading
Read NowMost Popular - A ravenous bull and bear community has developed around Peregrine Pharmaceuticals (NASDAQ:PPHM), and thus far, the bulls have scored big. The company answered most of … Continue Reading
Read NowMost Popular - Stem Cells Inc, (NASDAQ:STEM), developer of stem cell-based treatments for spinal injuries, is up for the second day in a row Friday in pre-market trading … Continue Reading
Read Now